Author: OurCrowd

[Alpha Tau in GlobeNewswire] Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with squamous cell carcinoma of the vulva has been treated in a feasibility and safety study of Alpha DaRT at Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust in Cambridge, England. Read...

Read More